NK1 receptor (TACR1)
The substance P receptor that drives the delayed nausea felt in the days after chemotherapy. Aprepitant and netupitant block it and are combined with a 5-HT3 blocker and dexamethasone for the most nausea-provoking regimens. This dossier gathers the 0 products (0 approved), 0 trials, 0 pathways and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
Biology
G protein-coupled receptor for substance P in the nucleus tractus solitarius and area postrema; blocked by pitant antiemetics.
- Supportive care: prevention of delayed chemotherapy-induced nausea and vomiting
External identifiers
Built from HGNC, Ensembl, UniProt and ChEMBL idsProducts by modality and phase
Browse products →No product in the corpus is aimed at this target yet.
Trials
Evidence ranking →No trial in the corpus names this target or one of its products.
Resistance routes
Unaddressed routes →The resistance atlas has no route that names this target.
Pathways
Pathway-to-drug matrix →No pathway diagram carries this target as a node.
Companion diagnostics
Assay registry →No companion diagnostic in the registry measures this target.
Preclinical models
All models →No model entry for this target yet; check the cancer entries on the models page.
Open questions
All open questions →No open questions recorded for this target yet. Suggest one.
Literature
Preprints →Query for this target: (TITLE:"NK1 receptor" OR ABSTRACT:"NK1 receptor" OR TITLE:"TACR1" OR ABSTRACT:"TACR1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about NK1 receptor (TACR1), not a curated reading list.
Export
The dossier as machine-readable JSON: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/tacr1.json. Licence CC BY-NC 4.0.